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Extracellular chaperones prevent Aβ42-induced toxicity in rat brains
Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterised by cognitive decline,
formation of the extracellular amyloid β (Aβ42) plaques, neuronal and synapse loss, and activated microglia
and astrocytes. Extracellular chaperones, which are known to inhibit amyloid fibril formation and promote
clearance of misfolded aggregates, have recently been shown to reduce efficiently the toxicity of HypF-N
misfolded oligomers to immortalised cell lines, by binding and clustering them into large species. However,
the role of extracellular chaperones on Aβ oligomer toxicity remains unclear, with reports often appearing
contradictory. In this study we microinjected into the hippocampus of rat brains Aβ42 oligomers preincubated for 1 h with two extracellular chaperones, namely clusterin and α2-macroglobulin. The chaperones
were found to prevent Aβ42-induced learning and memory impairments, as assessed by the Morris Water
Maze test, and reduce Aβ42-induced glia inflammation and neuronal degeneration in rat brains, as probed by
fluorescent immunohistochemical analyses. Moreover, the chaperones were able to prevent Aβ42
colocalisation with PSD-95 at post-synaptic terminals of rat primary neurons, suppressing oligomer
cytotoxicity. All such effects were not effective by adding pre-formed oligomers and chaperones without
preincubation. Molecular chaperones have therefore the potential to prevent the early symptoms of AD, not
just by inhibiting Aβ42 aggregation, as previously demonstrated, but also by suppressing the toxicity of Aβ42
oligomers after they are formed. These findings elect them as novel neuroprotectors against amyloid-induced
injury and excellent candidates for the design of therapeutic strategies against AD.
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Abstract
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterised by
cognitive decline, formation of the extracellular amyloid  (A42) plaques, neuronal and
synapse loss, and activated microglia and astrocytes. Extracellular chaperones, which are
known to inhibit amyloid fibril formation and promote clearance of misfolded aggregates,
have recently been shown to reduce efficiently the toxicity of HypF-N misfolded oligomers
to immortalized cell lines, by binding and clustering them into large species. However, the
role of extracellular chaperones on A oligomer toxicity remains unclear, with reports often
appearing contradictory. In this study we microinjected into the hippocampus of rat brains
Aβ42 oligomers pre-incubated for 1 h with two extracellular chaperones, namely clusterin and
2-macroglobulin. The chaperones were found to prevent Aβ42-induced learning and memory
impairments, as assessed by the Morris Water Maze test, and reduce Aβ42-induced glia
inflammation and neuronal degeneration in rat brains, as probed by fluorescent
immunohistochemical analyses. Moreover, the chaperones were able to prevent Aβ42
colocalization with PSD-95 at post-synaptic terminals of rat primary neurons, suppressing
oligomer cytotoxicity. All such effects were not effective by adding pre-formed oligomers
and chaperones without preincubation. Molecular chaperones have therefore the potential to
prevent the early symptoms of AD, not just by inhibiting A42 aggregation, as previously
demonstrated, but also by suppressing the toxicity of A42 oligomers after they are formed.
These findings elect them as novel neuroprotectors against amyloid-induced injury and
excellent candidates for the design of therapeutic strategies against AD.

Keywords: extracellular chaperones, amyloid neurotoxicity, hippocampal injury, learning
impairment, memory injury, A42/PSD-95 colocalization
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Highlights
- Chaperones prevented learning and memory impairment in rats in which Aβ42 was injected
into the hippocampus
- Chaperones reduced inflammation and neurodegeneration in Aβ42-exposed rat hippocampus
- Chaperones suppress A42 oligomer-induced cytotoxicity in rat primary neurons
- Chaperones inhibit colocalization of Aβ42 aggregates with PSD-95

Abbreviations: α2-macroglobulin (α2M), Alzheimer’s disease (AD), amyloid-beta peptide
(Aβ), bovine serum albumin (BSA), Central Nervous System (CNS), clusterin (Clu), 2’,7’dichlorodihydrofluorescein

diacetate

(CM-H2DCFDA),

dimethylsulfoxide

(DMSO),

dithiothreitol (DTT), Dulbecco’s phosphate-buffered saline (D-PBS), embryonic day (ED),
ethylene diamine tetraacetic acid (EDTA), ethylene glycol tetraacetic acid (EGTA), fetal
bovine serum (FBS), glial fibrillary acidic protein (GFAP), haptoglobin (Hp), ionized
calcium binding adaptor molecule 1 (Iba-1), Morris water maze test (MWM), 3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), neurobasal medium (NBM),
neuronal nuclei (Neu-N), normal goat serum (NGS), N-terminal domain of the HypF protein
from Escherichia coli (HypF-N), phenylmethylsulfonyl fluoride (PMSF), postsynaptic
density protein 95 (PSD-95).

3

1. Introduction
Alzheimer’s disease (AD) is a progressive human neurodegenerative disorder
characterised by cognitive decline, neuronal and synapse loss, and the formation of two
pathological lesions, extracellular amyloid plaques composed largely of the amyloid-
peptide (Aβ), and intracellular neurofibrillary tangles formed by the hyperphosphorylated tau
protein [1]. Impairment in synaptic function and plasticity might be the most significant early
event in the pathogenesis of AD [2,3], with such events being particularly relevant in the
hippocampal region [4].
Clinicopathological hallmarks of AD correlate with the presence of soluble Aβ oligomers
as the principal neurotoxic agent [2,5,6]. It has been demonstrated that synaptic plasticity is
rapidly disrupted by Aβ42 oligomers [7-12]. Moreover, Aβ oligomers have been found to
colocalize with postsynaptic density protein 95 (PSD-95) in hippocampal and cortical
primary neurons [13-15] and impair cognitive functions of animal models when
microinjected in their brains [5,16]. PSD-95 is a critical scaffolding component of
postsynaptic terminals found in excitatory Central Nervous System (CNS) signaling
pathways [17] and clusters of PSD-95 have been established previously as definitive markers
for postsynaptic terminals in mature hippocampal and cortical cell cultures [18-20]. In
addition, the concentration of PSD-95 in the brain of AD patients is significantly lower than
that of normal brains [21]. Aβ also plays a central role in the pathogenesis of AD as a
mediator of oxidative stress and neuronal cell apoptosis [22-29].
Neurons are not the only cell type in the brain that is affected in AD; vulnerable brain
regions exhibit activated microglial cells and astrocytes, which often associate with amyloid
deposits suggesting a central role of these non-neuronal cells in AD pathology [30-33]. It has
also been suggested that atrophy of astroglia, which occurs at the early stages of AD and is
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likely to accompany early stages of other neurodegenerative diseases, determines synaptic
malfunction, synaptic loss, and cognitive deficits [34].
Molecular chaperones are proteins that play a central role in the avoidance of protein
misfolding and aggregation [35,36]. Chaperones are known to have a range of different
functions, such as assisting protein folding [35], inhibiting protein aggregation [37], causing
the disaggregation of aberrant protein oligomers [38], and facilitating the degradation of
misfolded proteins [39]. In particular, extracellular chaperones, such as clusterin (Clu),
haptoglobin (Hp) and α2-macroglobulin (α2M), have been shown to colocalize with amyloid
plaques in AD [40-42], inhibit Aβ fibril formation in vitro [43-47] and promote the clearance
of protein aggregates via endocytosis [48-50]. It is unclear, however, whether extracellular
chaperones inhibit directly the toxicity of A oligomers, as reports have often been
contradictory, with a few of them supporting a toxicity-enhancing role [7,51,52], others
claiming a protective action [43,53,54] and one report describing a dose-dependent effect
[46].
Our recent data showed that a representative set of chaperones can inhibit efficiently the
toxicity of extracellularly added protein oligomers formed by three different peptides and
proteins in SH-SY5Y neuroblastoma cells, provided the chaperones are incubated with the
preformed oligomers before the resulting mixtures are added to the extracellular medium of
the cells [54]. Such an inhibition is very effective as it occurs even at low chaperone
concentration [54]. Using preformed HypF-N oligomers as a representative toxic species, the
protective effect of the chaperones was shown to result from the ability of these proteins to
bind to the oligomers and promote their further assembly into larger species, in the absence of
any significant reorganisation of their internal molecular structure [54].
Following this encouraging result obtained with HypF-N oligomers and cultured neuronal
cells, the purpose of this study was to determine whether pre-incubation of Aβ42 oligomers
5

with two types of extracellular chaperones can prevent Aβ42-induced hippocampal injury in
rats following hippocampal microinjection and to determine how it correlates with reduced
brain pathology and behavioural injuries. In these experiments, toxic oligomers from Aβ42
were formed, incubated with Clu or α2M, and then injected into rat brains or added to the
extracellular medium of rat primary neurons. Thus, the oligomers were formed before adding
the chaperones, with the aim of assessing whether the protective action of the latter also
includes neutralisation of toxic oligomers after they have formed. We demonstrate that the
chaperones ameliorate the Aβ42-mediated learning and memory impairment in injected rats,
reduce Aβ42-induced glia inflammation and neuronal degeneration in injected rat brains and
protect against the oxidative-stress conditions and apoptotic cell death associated with Aβ42
exposure. In addition, the extracellular chaperones were found to prevent Aβ42 binding to
PSD-95 in dendritic spines, neutralising oligomer toxicity in cultured rat primary neurons.

2. Materials and Methods
2.1. Formation of Aβ42 oligomers
A42 were obtained from Sigma-Aldrich (St. Louis, MO). Human Clu and α2M were
purified as previously reported [55,56]. Aβ42 oligomers were prepared as previously
described [57] and resuspended in F12-medium to 12 μM. Native proteins were diluted to 12
μM into the same medium. Oligomers were incubated in the medium for 1 h at 37 °C while
shaking, without or with chaperones, and then injected into rats or added to cultured cells.
The oligomer:chaperone molar ratio was 10:1 for Clu and 100:1 for α2M (Aβ42 is considered
as monomers, Clu as α dimers and α2M as a tetramer, according to the functional oligomeric
state).

6

2.2. Rat model and cell cultures
Thirty-six three-month-old (220–250 g) male Wistar rats (Harlan Nossan, Correzzana,
Italy) were housed in macrolon cages until surgery and maintained on a 12-hour light/dark
cycle at 23 °C. All animal manipulations were performed in vivo, according to the European
Community guidelines for animal care (DL 116/92).
Primary cortical and hippocampal neurons were obtained from embryonic day (ED)-17
Sprague-Dawley rats (Harlan) as described in Bongers et al. [58]. The experimental
procedures were in accordance with the standards set forth in the Guide for the Care and Use
of Laboratory Animals (published by the National Academy of Science, National Academy
Press, Washington, D.C.). The uteri were removed from the gravid rat under anaesthesia.
Cerebral cortices and hippocampi were dissociated in sterile Dulbecco’s phosphate-buffered
saline (D-PBS; Sigma), and neurons isolated in the same medium containing trypsin (0.5% in
D-PBS) for 10 min at 37° C. After centrifugation at 2000 rcf for 5 min, dissociated neurons
were re-suspended in neurobasal medium (NBM; Gibco, Invitrogen Corporation, Milan,
Italy) supplemented with 2% (v/v) B-27 (Gibco) and 0.5 mmol/L glutamine (Gibco), and then
plated in poly-L-lysine-coated 96 or 24-well plates at densities of approximately 1.0 x
104/well and 2.0 x 104/well, respectively. Cultures were maintained in NBM at 37° C in a 5%
CO2-humidified atmosphere. Neurons were exposed to 12 μM toxic oligomers 14 days after
plating.

2.3. Morris water maze test (MWM)
For in vivo studies, Aβ42 oligomers and chaperones were suspended in F12-medium with
0.1% DMSO at final concentrations of 0.45 mg/ml (100 µM) and 0.7 mg/ml (10 µM for Clu
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and 1 µM for α2M), respectively, and incubated for 1 h at 37 °C while shaking. 1.5 µl
aliquots of F12-medium, F12-medium with Aβ42 oligomers, F12-medium with Aβ42
oligomers and Clu and F12-medium with Aβ42 oligomer and α2M, all containing 0.1%
DMSO, were injected into the Cornu Ammonis (CA) 1 molecular layer of the right
hippocampus of anaesthetised (Zoletyl, 45 mg/kg plus Carprofen, 5 mg/kg) rats for each
condition, using a Hamilton microsyringe, at the following stereotaxic coordinates (in mm):
AP,-3.7; L,-2.5 from bregma; and H, 3.5 below the dura [59]. The injections lasted 3 min, and
the microsyringe was left in the place for 5 min after completing the infusion. Rats were
behaviourally tested in the MWM 1 week after the intrahippocampal injection of the different
oligomers (n=6/group). This was considered a reasonable time period to allow us to detect
long-term effects of the injected aggregates in light of their likely persistence in tissue.
The water maze apparatus consisted of a circular pool (160 cm diameter and 45 cm high)
made of plastic. The pool was filled to a depth of 30 cm with water (22±1 °C) that was made
dark by the addition of non-toxic dark paint, and virtually divided into four equivalent
quadrants. Rats were tested in the reference memory version of MWM with the procedure
previously described [60]; briefly, all rats underwent a reference memory training with a
hidden platform (13 cm diameter, submerged 0.5 cm under the water level), placed in the
centre of one quadrant of the pool (northwest) for 4 days, with 4 trials per day, with the four
starting locations varied between trials. Upon release into the water, the rat was allowed to
search the platform for 60 s; if the platform was not located within the maximum time of 60
s, the rat was guided to the location. The rat was allowed 20 s on the platform. Extra-maze
visual cues around the room remained in fixed positions throughout the experiment. For each
trial, latency to find the platform (maximum 60 s) was recorded by a videotracking/computer-digitising system (HVS Image, Hampton, UK). On day 4, five hours after
the last trial, the platform was removed from the pool and each rat received one 30 s swim
8

"probe trial". The starting point was set in the south-east quadrant. Percentage of time spent
in each quadrant and the number of crossing over the platform section were recorded.

2.4. Fluorescence immunohistochemical analyses of glial activation and Neu-N
After behavioural evaluations, all rats were deeply anaesthetised with chloral hydrate (400
mg/kg, i.p.) and killed by decapitation. Four brains for each conditions were quickly
extracted and fixed in phosphate-buffered 4% paraformaldehyde (pH 7.4) for 24 h at 4 °C,
subsequently rinsed with PBS, dehydrated using an automated machine and embedded in
paraffin. Coronal sections (5.0 µm) were cut using a microtome and mounted on slides.
Sections were then incubated in xylene for 20 min at room temperature, to allow removal of
paraffin, and subsequently rehydrated.
Fluorescent labeling followed previously described protocols [61]. Briefly, 5 µm paraffinembedded coronal sections (3 sections of each brain for each condition) were rinsed 3 times
and placed in blocking solution (PBS, pH 7.4 + 0.3% (v/v) Triton X-100, 2 g/l bovin serum
albumin (BSA) and 5% (v/v) normal goat serum (NGS)) for 30 min at room temperature
(RT). Analysis of glial fibrillary acidic protein (GFAP)-immunoreactive astrocytes and
ionised calcium binding adaptor molecule 1 (Iba-1)-labeled microglial cells were carried out
overnight at 4 °C using 1:500 diluted rabbit polyclonal anti-GFAP (Dako, Glostrup,
Denmark) or 1:300 diluted rabbit polyclonal anti-Iba 1 (Wako, Fuggerstrasse, Germany)
antibodies diluted in fresh blocking solution. Sections were then washed in PBS (3x 10 min)
at RT and subsequently incubated for 2 h with Alexa Fluor 488-conjugated anti-rabbit or
Alexa Fluor 594-conjugated anti-rabbit polyclonal antibodies (Invitrogen, Eugene, OR),
diluted 1:400 in blocking solution. Following further rinses, sections were cover-slipped
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using Vectashield water-based mounting medium containing DAPI (Vector Laboratories,
Burlingame, CA).
Analysis of neuronal nuclei (Neu-N) were carried out overnight at 4 °C using 1:100
diluted mouse polyclonal anti-Neu-N (Chemicon, Millipore, Italy) antibodies diluted in fresh
blocking solution. Sections were then washed in PBS (3x 10 min) at room temperature and
subsequently incubated for 2 h with Alexa Fluor 594-conjugated anti-mouse polyclonal
antibodies (Invitrogen) diluted 1:400. Following further rinses, sections were cover-slipped
using Vectashield water-based mounting medium containing DAPI (Vector Laboratories). In
each study the analysis of negative controls (omission of primary antibody) was
simultaneously

performed

in

order

to

exclude

the

presence

of

non-specific

immunofluorescent staining, cross-immunostaining, or fluorescence bleed-through. Neu-Npositive cells in the hippocampus were counted under a 10 x objective lens of an Olympus
Optical (Tokyo, Japan) BX63 microscope equipped with an Olympus Optical DP50 digital
camera and a cellSens Dimension software. The total number of counted Neu-N-positive
cells, carried out on 3 sections of each brain for each condition, was averaged, expressed as
percentage of that in the F-12-injected rats, assumed as 100% and analyzed using Prism 3.0
(GraphPad Software, San Diego, CA).

2.5. Lipid peroxidation analysis and caspase-3 activity assay in rat hippocampus
The analyses of lipid peroxidation and caspase-3 levels were performed on rat
hippocampal homogenates. We microinjected 1.5 µl aliquots of F12-medium, Aβ42 oligomers
and Aβ42 oligomer pre-incubated with Clu or α2M for 0 h and 1 h, into the right hippocampus
of anaesthetised rats. Three hippocampi for each condition were quickly extracted from rat
brains and immediately stored at -80 °C. Each hippocampus was transferred to ice-cold
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microcentrifuge tubes with 200 µl of lysis buffer (50 mM Tris–HCl, pH 7.5, 50 mM NaCl, 10
mM EGTA, 5 mM EDTA, 2 mM sodium pyrophosphate, 4 mM para-nitrophenylphosphate, 1
mM sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride (PMSF), plus 20 µg/ml
leupeptin and 30 µg/ml aprotinin), and tissues were homogenised on ice (with a PotterElvehjem homogeniser) directly into the Eppendorf tube (20 strokes, 1 stroke/s). Immediately
after homogenisation, protein determination was performed using the method of Bradford
[62]. To assess the rate of lipid peroxidation, the 8-OH isoprostane levels were measured in
rat hippocampal homogenates (5 µg of proteins per well) using the 8-isoprostane EIA kit
(Cayman Chemical Company, Ann Arbor, MI) at 405 nm, as previously described [63].
The caspase-3 activity assay homogenates were prepared using a different buffer
composition (20 mM Tris-HCl buffer, pH 7.4, containing 250 mM NaCl, 2 mM EDTA, 0.1%
Triton X-100, 5 µg/ml aprotinin, 5 µg/ml leupeptin, 0.5 mM phenylmethylsulfonyl fluoride, 4
mM sodium vanadate, and 1 mM dithiothreitol (DTT)) [64]. To evaluate the caspase-3
activation, 50 μg of total proteins were diluted in 50 mM HEPES-KOH buffer, pH 7.0,
containing

10%

glycerol,

0.1%

3-[(3-cholamidopropyl)dimethylammonio]-

1-

propanesulfonate, 2 mM EDTA, 10 mM DTT and incubated for 4 h at 37 °C in presence of
30 μM Ac-DEVD-AFC (excitation, 400 nm; emission, 505 nm) (Biomol Research
Laboratories Inc., Plymouth Meeting, PA, http://www.biomol.com).

2.6. MTT reduction assay in cultured neurons
To assess the effects of chaperones on the Aβ42 oligomer cytotoxicity, we evaluated the
mitochondrial status using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay, on primary rat hippocampal and cortical neurons seeded in 96-well plates for
24 h at 37 °C. The MTT reduction assay was performed as described [65]. Preformed
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oligomers of Aβ42 (12 µM monomer concentration) were incubated in cell culture medium
for different time lengths (0, 5, 15, 30 and 60 min) in the absence or presence of Clu or α2M
(Aβ42:chaperone molar ratio was 10:1 and 100:1 for Clu and α2M, respectively) and then
added to rat neurons for 24 h.

2.7. Measurement of intracellular ROS in cultured neurons
Preformed oligomers of Aβ42 (12 µM monomer concentration) were incubated for 0 h and
1 h in the cell culture medium with or without Clu or α2M (oligomer:chaperone molar ratios
as described above) and then added to rat neurons seeded on glass coverslips for 60 min at 37
°C. To detect intracellular ROS production, neurons were then loaded with 10 µM 2’,7’dichlorodihydrofluorescein diacetate (CM-H2DCFDA, Molecular Probes), as described
previously [66]. Cell fluorescence was analyzed by the confocal scanning microscope
described above using the 488 nm excitation line.

2.8. Colocalization of Aβ42 aggregates with PSD-95 in cultured neurons
Preformed oligomers of Aβ42 (12 µM monomer concentration) were incubated for 1 h in
the cell culture medium with or without Clu or α2M (Aβ42:chaperone molar ratio as described
above) and then added to rat neurons seeded on glass coverslips for 1 h or 24 h at 37 °C.
Immunolabeling of cultured primary neurons was performed as previously described [14].
The colocalization of Aβ42 aggregates with PSD-95 was monitored using 1:200 mouse
monoclonal 6E10 antibody and 1:500 rabbit polyclonal anti-psd-95 antibody (Pierce
Biothecnology, USA) for 60 min at 37 °C, and then with Alexa Fluor 488- and 594conjugated antibody (Sigma-Aldrich, St. Louis, MO) for 2 h at room temperature. Cell
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fluorescence was analyzed by confocal Leica TCS SP5 scanning microscope (Mannheim,
Germany) equipped with laser sources for fluorescence measurements at 488 and 594 nm and
a Leica Plan Apo 63X oil immersion objective. A series of optical sections (1024x1024
pixels), 1.0 µm in thickness, were taken through the cell depth for each examined sample.
Settings were maintained constant for each analysis. The colocalization of oligomers with
PSD-95 was estimated on regions of interest (12–13 cells) using the ImageJ (NIH, Bethesda,
MD, USA) and JACOP plugin (rsb.info.nih.gov) softwares [67].

2.9. Statistical analysis
MWM data are expressed as mean ± standard error of the mean (SEM). MTT test, 8-OH
isoprostane test and caspase-3 assay were expressed as mean  standard deviation (SD).
Comparisons between different groups were performed using ANOVA followed by
Bonferroni’s post-comparison test. A p-value less than 0.05 was accepted as statistically
significant.

3. RESULTS
3.1. Chaperones prevented learning and memory impairment in intra-hippocampus Aβ42
injected rats
Aβ42 oligomers were incubated for 1 h in F-12 medium in the absence or presence of two
types of extracellular chaperones, namely clusterin (Clu) and α2-macroglobulin (α2M). 1.5 µl
aliquots (0.7 µg Aβ42 with. 1 µg Clu or α2M) were microinjected into the right hippocampus
of rat brains. Seven days after unilateral injection into the hippocampus, rats were trained for
four days in the Morris water maze (MWM) to learn where the hidden platform was located.
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The ability of rats to acquire, process, and recall spatial information was assessed by
evaluation of the time required to find the platform (escape latency), time in quadrant where
the platform is located (target quadrant), time in the opposite quadrant, time in the small area
where the platform is located (platform section) and number of crossings over the platform
section. The animals were naive to the water maze and showed no deficiencies in swimming
abilities, directional swimming toward the platform, or climbing onto a hidden platform
during training trials. Rats injected only with F12-medium shortened the escape latency
during the 4-days training phase (Fig. 1A). They were good swimmers and responded to
being placed in water with an appropriate swim-search response. Conversely, Aβ42 oligomerinjected rats showed only a slow decrease in escape latency during the 4 days of training (Fig.
1A). When we pre-incubated Aβ42 oligomers with Clu or α2M for 1 h and then injected these
solutions intra hippocampus, we obtained a significant decrease (p<0.05) in escape latency,
compared with the Aβ42 oligomer-administered group, particularly at day 3 and 4 (Fig. 1A).
Five h after the last test on day 4 it was found that rats treated with Aβ42 oligomers preincubated with Clu or α2M for 1 h spent a significantly higher percentage of time in the target
quadrant (p<0.05), with respect the animals treated with only Aβ42 oligomers (Fig. 1B, top
left). We also observed a marked reduction of the percentage of time spent in the opposite
quadrant (P<0.05) in rats treated with Aβ42 oligomers plus Clu or α2M, compared to Aβ42
oligomer-injected rats (Fig. 1B top right). The percentage of time spent in the adjacent
quadrants and the swim speed in target quadrant during this session was comparable among
the groups (data not shown), indicating that the motility of rats injected with the different
samples was not impaired. The analysis of the percentage of time in the platform section
showed a significant increase in rats treated with Aβ42 oligomers plus chaperones, with
respect to the Aβ42 oligomer-treated group (Fig. 1B, bottom left). Finally, the number of
crossings over the platform position revealed a significant increase in rats injected with Aβ42
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oligomers plus chaperones, compared to the Aβ42 oligomer-administered group (Fig 1B,
bottom right). Taken together, these data demonstrated that both types of extracellular
chaperones have the ability to prevent the learning and memory impairment mediated by the
intra hippocampus injection of Aβ42 oligomers.
3.2. Chaperones reduced glial reaction in Aβ42 exposed rat hippocampus
We then investigated whether chaperones could neutralise Aβ42-mediated glial
inflammation, by evaluating glial fibrillary acidic protein (GFAP)-immunoreactive astrocytes
and Iba 1-labelled microglial cells. Immunofluorescence analyses revealed diminished glial
reaction in rats treated with Aβ42 oligomers and chaperones compared to rats treated with
Aβ42 oligomers only (Fig. 2). Such a decrease was evident by monitoring both GFAPimmunoreactive astrocytes (Fig. 2A) and Iba 1-labelled microglial cells (Fig. 2B).
Hypertrophic astrocytes with long, thick branches were detected by GFAP immunostaining in
Aβ42-injected rats (Fig. 2A). In contrast, in rats treated with Aβ42 and chaperones, astrocyte
activation occurred to a much lesser extent (Fig. 2A). Labeling with anti-Iba-1 antibodies
revealed microglia with small cell bodies and thin, elongated processes in rats treated with
Aβ42 plus Clu or α2M, compared to Aβ42-injected rats, where microglia with enlarged cell
bodies and short, thickened processes were found (Fig. 2B). This data therefore suggests that
these two extracellular chaperones can protect against the Aβ42 oligomer-mediated glial
inflammation.

3.3. Chaperones prevented neuronal degeneration in Aβ42 exposed rat hippocampus
In AD, the aggregated species of Aβ peptides interact with the plasma membrane of the
affected cells, triggering a free radical-mediated injury that ultimately results in cell
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degeneration [68]. The survival of neurons after treatment with Aβ42 oligomers plus Clu or
α2M was examined by using the Neu-N marker. The group injected with Aβ42 oligomers
showed a decreased number of mature neurons compared to the medium-administered group
(Fig. 3A). Conversely, rats treated with Aβ42 oligomers preincubated for 1h with Clu or α2M
showed a high improvement in neuron survival, suggesting that chaperones can prevent Aβ42mediated neurodegeneration.
We next evaluated the protective role of the two extracellular chaperones against Aβ42induced lipid peroxidation, determined by measuring 8-OH isoprostane levels. The results
showed that 8-OH isoprostane levels were significantly higher in the hippocampal
homogenates of rats treated with Aβ42 oligomers, compared to the medium-injected groups
(Fig. 3B), suggesting an oxidative-stressed condition associated with Aβ42 oligomer
exposure. 8-OH isoprostane levels were also high after injection of Aβ42 oligomers with Clu
or α2M in the absence of pre-incubation (Fig. 3B). In contrast, the hippocampi of rats treated
with Aβ42 oligomers and either chaperone in the presence of preincubation for 1 h before
injection showed no difference in the lipid peroxidation levels with respect to mediuminjected rats (Fig. 3B).
We then analyzed whether the two chaperones can prevent the Aβ42-induced cell death,
by measuring the activity of caspase-3, a well-recognised apoptotic marker, in rat
hippocampal homogenates [64]. Caspase-3 activation was significantly increased in the
hippocampal homogenates of rats injected with Aβ42 oligomers, with respect to the rats
injected only with F12-medium (Fig. 3C), indicating apoptotic cell death associated with
Aβ42 oligomer treatment. Caspase-3 activation was also increased in the hippocampal
homogenates of rats injected with Aβ42 oligomers plus Clu or α2M in the absence of preincubation (Fig. 3C). On the other hand, the level of caspase-3 activation in hippocampi of
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rats treated with Aβ42 oligomers pre-incubated with chaperones for 1 h was not significantly
different to that of rats injected only with F12-medium (Fig. 3C).
These results suggest that the pre-incubation of Aβ42 oligomers with chaperones prevents
the oxidative-stress conditions associated with Aβ42 oligomer exposure, avoiding the
induction of apoptosis by the oligomers.

3.4. Chaperones suppress A42 oligomer-induced cytotoxicity in rat hippocampal and
cortical neurons
To assess the protective role of the two extracellular chaperones against Aβ42 oligomers,
we also used cultures of hippocampal and cortical neurons extracted from embryonic day
(ED)-17 rats and analyzed in their mature form at day 21. In a first set of experiments we
incubated preformed oligomers of A42 in the cell culture medium in the absence or presence
of Clu or α2M for different time lengths, and then added the resulting mixture to the
extracellular medium of cultured primary hippocampal neurons. A42 oligomers showed their
toxic action (Fig. 4A), whereas the neurons treated with oligomers pre-incubated with Clu or
α2M were found to reduce MTT to levels similar to medium-administered cells (Fig. 4A) and
to cells treated with native A42 (data not shown), with an effect dependent on the time of
preincubation of the oligomers with the chaperones. Similar data was obtained by preincubating A42 oligomers plus chaperones for 1 h in cultured primary cortical neurons (Fig.
4B). Comparable results were achieved with preformed oligomers of the N-terminal domain
of the HypF protein from Escherichia coli (HypF-N) (Suppl. Fig. 1A and B). HypF-N is a
valuable model system for investigating the structural basis of the cellular dysfunction caused
by misfolded protein oligomers, because this protein have the same morphological and
tinctorial features as those formed by disease-related peptides and proteins [65].
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Then we compared the ability of the two extracellular chaperones to suppress the
intracellular ROS production and Ca2+ dyshomeostasis induced by A42 oligomers. A42
oligomers induced a sharp increase in ROS (Fig. 4C,D) and cytosolic free Ca2+ (Suppl. Fig.
2) in rat neurons, which was inhibited by Clu and α2M (Fig. 4C and D and Suppl. Fig. 2).
Such inhibitory effects were not found when the oligomers and the chaperones were added to
the rat neurons in the absence of pre-incubation (Fig. 4C and Suppl. Fig. 2A), suggesting the
importance of the pre-incubation time. Comparable results were obtained with HypF-N
oligomers (Suppl. Fig. 1C and D and Suppl. Fig. 3).
These results therefore indicate that pre-incubation of Aβ42 oligomers with the two
chaperones can suppress or decrease markedly the oxidative stress, calcium dishomeostasis
and toxicity caused by A42.

3.5. Chaperones inhibit colocalization of Aβ42 aggregates with PSD-95 preventing synaptic
dysfunction
We next investigated by confocal microscopy whether chaperones prevent the
colocalization of Aβ42 aggregates with PSD-95. The scatter plots of fluorescence signals over
the highlighted areas are shown in Fig. 5. A notable degree of colocalization between Aβ42
oligomers and PSD-95 was observed in neurons treated for 1 h with Aβ42 oligomers, with
respect to medium-administered neurons (Fig. 5). Conversely, when we treated the neurons
for 1 h with Aβ42 oligomers pre-incubated with either Clu or α2M, the chaperones were found
to inhibit oligomer binding to the cell membrane thus preventing the colocalization with PSD95 (Fig. 5, 18 dendrite sections were analyzed for each samples). The fraction of Aβ42 puncta
colocalizing with PSD-95 puncta was 1.2 ± 0.5% for medium-administered neurons, 59.9 ±
2.0% for neurons treated for 1 h with Aβ42 oligomers, 26.3 ± 1.8% for neurons treated for 1 h
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with Aβ42 oligomers plus Clu, 26.9 ± 1.9% for neurons treated for 1 h with Aβ42 oligomers
plus α2M. Similar data was achieved analyzing the colocalization between HypF-N oligomers
and PSD-95 (Suppl. Fig. 4).
The concentration of PSD-95 has been found to be significantly lower in the brain of AD
patients with respect to normal brains [21]. Thus, we evaluated whether the prolonged
treatment of rat hippocampal neurons with A42 oligomers decrease PSD-95 levels. When we
treated the neurons with Aβ42 oligomers for 24 h, we observed a lower degree of
colocalization with PSD-95 caused by a decreased expression of PSD-95 (Fig. 5). In
particular, in neurons treated for 24 h with Aβ42 oligomers the fraction of Aβ42 puncta
colocalizing with PSD-95 puncta (29.3 ± 2.8%) was comparable to that observed in neurons
treated for 24 h with Aβ42 oligomers plus Clu or α2M (24.6 ± 1.9% or 24.5 ± 1.7%,
respectively). Similar data was achieved analyzing the colocalization between HypF-N
oligomers and PSD-95 (Suppl. Fig. 4).
These results show that A42 oligomers induce a decrease in PSD-95 levels in a timedependent manner, as previously reported with Aβ40 [69], supporting a model of AD
pathogenesis in which soluble Aβ may be responsible for the cognitive impairment through
synaptic dysfunction [3]. In addition, the two extracellular chaperones studied here are able to
recover PSD-95 expression, avoiding oligomer binding to the synapses, suggesting an
important protective effect of chaperones against oligomer-induced synaptic dysfunction.

4. DISCUSSION
Clusterin (Clu) and α2-macroglobulin (α2M) are markedly induced in neuropathological
conditions such as AD, where they are found associated with Aβ plaques, suggesting a
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physiological interaction with Aβ [40-42,70-72]. Clu and α2M are also known to inhibit
amyloid fibril formation in vitro [43-47]. In particular, it has been shown that Clu binds to all
types of soluble oligomers found to be present during the aggregation and disaggregation of
Aβ40, preventing further growth and proliferation of aggregated species [73-77]. α2M was
also found to bind small oligomers, preventing their growth and/or conversion into fibrils
[47]. Furthermore, Clu and α2M are known to mediate the clearance of extracellular protein
oligomers via endocytosis [48-50]. It is unclear, however, if extracellular chaperones have an
ability to inhibit intrinsically the toxicity of A misfolded oligomers, with evidence that has
being very sparse and often contradictory so far. Indeed, some reports supported a toxicityenhancing role for extracellular chaperones [7,51,52], others claimed a protective action
[43,53,54] while one study demonstrated that the ratio of chaperone:A could determine
whether the effect was protective or enhanced toxicity [46].
Important suggestions have been obtained using chaperones distinct from extracellular
ones, or protein oligomers distinct from A oligomers. Indeed, it has been demonstrated that
intracellular chaperones can prevent the toxicity of Aβ oligomers, sequestering and
converting them into large non toxic aggregates [78]. Our recent data showed that different
chaperones, including Clu and α2M, can inhibit efficiently the toxicity of extracellularly
added protein oligomers formed by three different peptides and proteins in SH-SY5Y
neuroblastoma cells, provided the chaperones are incubated with the preformed oligomers
before the resulting mixtures are added to the extracellular medium of the cells [54]. Such an
inhibition is very effective as it occurs even at low chaperone concentration [54]. Using
HypF-N oligomers as a toxic species, the protective effect of the chaperones was found to
result from the ability of these proteins to bind to the oligomers and promote their further
assembly into larger species, in the absence of any significant reorganisation of their internal
molecular structure [54].
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The present work originated from this previous study and was targeted to A oligomers,
extracellular chaperones and a context closely related to AD, such as rat brains and cultured
neurons. We demonstrated that chaperones can inhibit in vivo the neurotoxicity of high
concentrations of pre-formed extracellular A oligomers. Such an ability adds to the wellestablished functions of extracellular chaperones in inhibiting protein aggregation [43-47]
and promoting the clearance of protein aggregates [48-50]. In all our experiments, the
oligomers are formed before adding the chaperones, showing that the protective action of the
latter also includes neutralisation of toxic oligomers after they have formed. Thus we can
hypothesize that chaperones neutralize A42 oligomers through a binding mechanism that
promote the seeding of larger species, as previously demonstrated with HypF-N oligomers
[54]. The accumulation of A fibrils as large plaques visible with optical microscopy and the
association of such plaques with extracellular chaperones is indeed suggestive of this
possibility.
Multiple lines of evidence indicate that there are two locales in which Aβ oligomers play
a role in AD pathogenesis and are implicated in a synaptic failure, namely the intraneuronal
and extracellular compartments [79-85]. A dynamic equilibrium seems to exist between the
pools of Aβ oligomers in the two locales; extracellular Aβ appears to originate from
intraneuronal Aβ [86]. Since A is released extracellularly from a membrane precursor
protein, A plaques accumulate extracellularly and A oligomers have an ability to impair
cell viability from the extracellular space, we have chosen to focus on extracellularly added
oligomers rather than intracellular ones in all our experiments.
This is the first report that molecular chaperones prevent A42-induced learning and
memory impairments in hippocampal-injected rat brains in vivo. Associated with this
prevention is the reduction of astroglial activation, astrogliosis, lipoperoxidation, and
caspase-3 activation in these brains. In addition, chaperones were found to be able to protect
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primary hippocampal and cortical neurons against injuries caused by misfolded A42
oligomers, by preventing A42 binding to the dendrites. In future experiments it will be
crucial to determine whether chaperone-mediated neutralization of A42 oligomers also act in
transgenic mouse models.
Hence, these data elect extracellular chaperones as novel molecules that are
neuroprotective against amyloid-induced injury and excellent candidates for the design and
development of therapeutic strategies for the prophylaxis and treatment of AD.
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Figure legends
Fig. 1 Effect of hippocampal injection of Aβ42 oligomers pre-incubated with two extracellular
chaperones (Clu and α2M) on MWM performance of rats. Rats were injected with 1.5 μl of
0.45 mg/ml Aβ42 oligomers in the absence or presence of 0.7 mg/ml chaperones (protein:Clu
molar ratio was 10:1; protein:α2M molar ratio was 100:1). Control rats were injected with 1.5
μl of medium. (A) Time lengths employed to find the platform during the training session
(escape latencies) are reported as mean ± SEM. Each point represents the mean daily value of
four trials of each experimental group (n=6 per group). (B) Percentage of time in the target
and opposite quadrants (top panels), percentage of time in the platform section and number of
crossings over the platform position (bottom panels) measured for 30 s on day 4. Data are
expressed as mean ± SEM. (n=6 per group). The asterisks and the double asterisks indicate
significant differences (p≤0.05 and p≤0.01, respectively) versus Aβ42-injected rats.
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Fig. 2 Analyses of glial activation in the hippocampus of 3-month-old male Wistar rats
treated with Aβ42 oligomers pre-incubated with extracellular chaperones. Representative
photomicrographs (10 x and 40 x magnifications) of fluorescence immunohistochemical
analyses of GFAP immunoreactivity (A) and Iba-1-labeled microglial cells (B) obtained 14 d
after injection of 1.5 µl medium, or 1.5 μl of 0.45 mg/ml Aβ42 oligomers in the absence or
presence of 0.7 mg/ml chaperones (protein:chaperone molar ratios as described in the
Materials and Methods section). GFAP immunoreactivity and Iba-1-labeling are indicated by
red and green colours, respectively.

Fig. 3 Analyses of neuronal degeneration, lipid peroxidation and apoptosis in the
hippocampus of 3-month-old male Wistar rats treated with Aβ42 oligomers pre-incubated
with extracellular chaperones. (A) Representative photomicrographs (40 x magnifications) of
fluorescence immunohistochemical analysis of Neu-N obtained 14 d after injection of 1.5 µl
medium, or 1.5 μl of 0.45 mg/ml Aβ42 oligomers in the absence or presence of 0.7 mg/ml
chaperones (protein:chaperone molar ratio as described in the Materials and Methods
section). The quantification of Neu-N immunoreactivity in the hippocampus after the
injections are shown below the images. (B) 8-OH isoprostane levels, a correlate of lipid
peroxidation, in rat hippocampal homogenates (5 µg of proteins per well) at the indicated
36

time lengths of pre-incubation between Aβ42 oligomers and chaperones. (C) Caspase-3 levels
assessed by a fluorimetric assay using the Ac-DEVD-AFC probe, at the indicated time
lengths of pre-incubation between Aβ42 oligomers and chaperones. The reported values
(means  SD) are representative of three independent experiments carried out in triplicate for
each experimental group (n=6 per group). The double and the triple asterisks indicate
significant differences (p≤0.01 and p≤0.001, respectively) versus Aβ42-injected rats.

Fig. 4 Suppression of Aβ42 oligomer toxicity by chaperones in rat primary neurons.
Preformed Aβ42 oligomers were incubated in the absence or presence of the indicated
chaperones (Aβ42:chaperone molar ratios as described in the Materials and Methods section)
for the indicated time lengths (A) and for 1 h (B) and then added to the extracellular medium
of hippocampal (A) or cortical (B) neurons for 24 h. (C,D) Representative confocal scanning
microscope images showing intracellular ROS levels in primary hippocampal (C) and
cortical (D) neurons from rat brains. Preformed Aβ42 oligomers were incubated in the absence
or presence of the indicated chaperones (protein:chaperone molar ratio as described in the
Materials and Methods section) for the indicated time lengths and then added to the
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extracellular medium of hippocampal (C) or cortical (D) neurons for 1 h. The green
fluorescence arises from the CM-H2DCFDA probe that has reacted with ROS. The
corresponding semi-quantitative values of the green fluorescence signal are shown below the
confocal images. In all histograms, the values reported are means ± SD of three independent
experiments carried out in triplicate. The single, double and triple asterisks indicate
significant differences (p≤0.05, p≤0.01 and p≤0.001, respectively) versus neurons treated
with Aβ42 oligomers.

Fig. 5 Representative confocal scanning microscope images showing Aβ42 oligomers
colocalizing with post synaptic densities in rat primary hippocampal neurons. Preformed
Aβ42 oligomers were incubated in the absence or presence of the indicated chaperones
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(protein:chaperone molar ratios as described in the Materials and Methods section) for 1 h
and then added to the extracellular medium of rat neurons for 1 h or 24 h, as indicated. Aβ42
aggregates and PSD-95 were monitored using mouse monoclonal 6E10 antibody and rabbit
polyclonal anti-PSD-95 antibody, respectively, and then with Alexa Fluor 488- and Alexa
Fluor 594-conjugated antibody (red and green fluorescence, respectively). The first line
showed medium-administered neurons; the second line shows neurons treated for 1 h (left) or
24 h (right) with Aβ42 oligomers (12 µM monomer concentration); the third and fourth lines
shows neurons treated for 1 h (left) or 24 h (right) with Aβ42 oligomers plus Clu (third line)
or 2M (fourth line). The cytofluorograms of dendrite sections show the red fluorescence
intensity (as pixel intensity, y axis) versus green fluorescence intensity (x axis). For each
sample, 18 cytofluorograms were analyzed, each considering one dendrite section. The
histograms show the percentage of colocalization on regions of interest (12–13 cells) using
the ImageJ (NIH, Bethesda, MD, USA) and JACOP plugin (rsb.info.nih.gov) softwares. Data
are expressed as mean ± S.D. (n=18 per group). The asterisks indicate significant differences
(p≤0.05) with respect to neurons treated for 1 h with Aβ42 oligomers.
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Supplementary materials
Formation of HypF-N oligomers
HypF-N was expressed, purified, and converted into toxic oligomers as previously reported
[60]. Oligomers were resuspended in the cell culture medium to 12 μM. Native proteins were
diluted to 12 μM into the same medium. Oligomers were then incubated in the appropriate media
for 1 h at 37 °C while shaking, in the absence or presence of chaperones, and then added to cultured
cells. The oligomer:chaperone molar ratio was 10:1 for Clu and 100:1 for α2M (HypF-N are
considered as monomers, Clu as α dimers and α2M as a tetramer, according to the functional
oligomeric state).

MTT reduction assay in cultured neurons
To assess the effects of chaperones on the HypF-N oligomer cytotoxicity, we evaluated the
mitochondrial status using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
assay, on primary rat hippocampal and cortical neurons seeded in 96-well plates for 24 h at 37° C.
The MTT reduction assay was performed as described [60]. Preformed oligomers of HypF-N (12
µM monomer concentration) were incubated in cell culture medium for 1 h in the absence or
presence of Clu or α2M (HypF-N:chaperone molar ratio was 10:1 and 100:1 for Clu and α2M,
respectively) and then added to rat neurons for 24 h.
1

Measurement of intracellular Ca2+ and ROS in cultured neurons
Preformed oligomers of Aβ42 (12 µM monomer concentration) were incubated for 0 h and 1 h in
the cell culture medium with or without Clu or α2M (oligomer:chaperone molar ratios as described
above) and then added to rat neurons seeded on glass coverslips for 60 min at 37 °C. Preformed
oligomers of HypF-N (12 µM monomer concentration) were incubated for 1 h in the cell culture
medium with or without Clu or α2M (oligomer:chaperone molar ratios as described above) and then
added to rat neurons seeded on glass coverslips for 60 min at 37 °C. To detect intracellular Ca2+ and
ROS production, neurons were then loaded with Fluo3-AM (Molecular Probes, Milan, Italy) or
with 2’,7’-dichlorodihydrofluorescein diacetate (CM-H2DCFDA, Molecular Probes, Milan, Italy),
respectively, as described previously [60,61]. Cell fluorescence was analysed by the confocal
scanning microscope described in the Materials and Methods section.

Colocalisation of Aβ42 aggregates with PSD-95 in cultured neurons
Preformed oligomers of HypF-N (12 µM monomer concentration) were incubated for 1 h in the
cell culture medium with or without Clu or α2M (HypF-N:chaperone molar ratio as described
above) and then added to rat neurons seeded on glass coverslips for 1 h or 24 h at 37 °C. The
colocalisation of HypF-N aggregates with PSD-95 was monitored using 1:200 diluted rabbit
polyclonal anti-HypF-N antibody (Primm S.r.l., Milan, Italy) and 1:500 mouse monoclonal antipsd-95 antibody (Vincibiochem, Florence, Italy) for 60 min at 37 °C, and then with Alexa Fluor
488- and 594-conjugated antibody (Sigma-Aldrich, St. Louis, MO) for 2 h at room temperature.
Cell fluorescence was analysed by the confocal scanning microscope described in the Materials and
Methods section.

2

Supplementary figures and legends

Figure. S1. Suppression of HypF-N oligomer toxicity by chaperones in rat primary neurons.
Preformed HypF-N oligomers were incubated for 1 h in the absence or presence of the indicated
chaperones (protein:chaperone molar ratio as described above) and then added to the extracellular
medium of hippocampal (A) or cortical (B) neurons for 24 h. Cell viability was expressed as
percent of MTT reduction in treated cells with respect to medium-administered cells (taken as
100%). (C,D) Representative confocal scanning microscope images showing intracellular ROS
levels in primary hippocampal (C) and cortical (D) neurons from rat brains. Preformed HypF-N
oligomers were incubated in the absence or presence of the indicated chaperones (protein:chaperone
3

molar ratio as described above) and then added to the extracellular medium of the neurons for 1 h.
The green fluorescence arises from the CM-H2DCFDA probe that has reacted with ROS. The
corresponding semi-quantitative values of the green fluorescence signal are shown below the
confocal images. The values reported are means ± SD of three independent experiments carried out
in triplicate. The asterisk and the triple asterisks indicate significant differences (p≤0.05 and
p≤0.001, respectively) vs neurons treated with HypF-N oligomers.

Figure. S2. Representative confocal scanning microscope images showing intracellular Ca2+ levels
in primary hippocampal (A) and cortical (B) neurons from rat brains. (A) Preformed Aβ42 oligomers
were incubated in the absence or presence of the indicated chaperones (protein:chaperone molar
ratio as described in the Materials and Methods section) for the indicated time lenghts and then
added to the extracellular medium of the hippocampal neurons for 1 h. (B) Preformed Aβ42
oligomers were incubated in the absence or presence of the indicated chaperones (protein:chaperone
molar ratio as described in the Materials and Methods section) for 1 h and then added to the
4

extracellular medium of cortical neurons for 1 h. In all images the green fluorescence arises from
the intracellular Fluo3 probe bound to Ca2+. The corresponding semi-quantitative values of the
green fluorescence signal are shown below the confocal images. The values reported are means ±
SD of three independent experiments. The triple asterisks indicate significant differences (p≤0.001)
vs neurons treated with Aβ42 oligomers.

Figure. S3. Representative confocal scanning microscope images showing intracellular Ca2+ levels
in primary hippocampal (A) and cortical (B) neurons from rat brains. Preformed HypF-N oligomers
were incubated in the absence or presence of the indicated chaperones (protein:chaperone molar
ratio as described above) and then added to the extracellular medium of the neurons for 1 h. In all
images the green fluorescence arises from the intracellular Fluo3 probe bound to Ca2+. The
corresponding semi-quantitative values of the green fluorescence signal are shown below the
confocal images. The values reported are means ± SD of three independent experiments. The triple
asterisk indicates significant differences (p≤0.001) vs neurons treated with HypF-N oligomers.
5

Figure. S4. Representative confocal scanning microscope images showing HypF-N oligomers
colocalising with post synaptic densities in rat primary hippocampal neurons. Preformed HypF-N
oligomers were incubated in the absence or presence of the indicated chaperones (protein:chaperone
molar ratio as described above) for 1 h and then added to the extracellular medium of rat neurons
for 1 h or 24 h, as indicated. HypF-N aggregates and PSD-95 was monitored using 1:200 diluted
rabbit polyclonal anti-HypF-N antibody and 1:500 mouse monoclonal anti-psd-95 antibody,
respectively, and then with Alexa Fluor 488- and Alexa Fluor 594-conjugated antibody (green and
red fluorescence, respectively). The first line showed medium-administered neurons, the second line
shows neurons treated for 1 h (left) or 24 h (right) with HypF-N oligomers (12 µM monomer
concentration) the third and fourth lines shows neurons treated for 1 h (left) or 24 h (right) with
HypF-N oligomers plus Clu (third line) or 2M (fourth line). The cytofluorograms of dendrite
sections show the green fluorescence intensity (as pixel intensity, y axis) vs red fluorescence
intensity (x axis). For each samples, 18 cytofluorograms were analysed, each considering one
dendrite section. The histograms show the percentage of colocalisation. Data are expressed as mean
± S.D. (n=18 per group). The asterisk indicates significant differences (p≤0.05) with respect to
neurons treated for 1 h with HypF-N oligomers.
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